Get the Weekly Intelligence Brief — top committee picks every Sunday.

HSIC vs TEVA

Henry Schein vs Teva Pharmaceutical Industries Limited — AI-powered side-by-side comparison
HSIC
Henry Schein
67
Buy
VS
TEVA
Teva Pharmaceutical Industries Limited
55
Watch
MetricHSICTEVA
AI Score 67 55
Price $89.16 $36.49
P/E Ratio 25.77× 57.19×
ROE 12.3% 17.8%
Revenue Growth YoY
Gross Margin 30.3% 52.5%
Debt / Equity 1.21× 2.16×
Dividend Yield 0.0% 0.0%
RSI (14) 59.4 77.8
Beta 0.808 0.864
Expected Upside +0.8%

AI Committee View

Current Innellis committee reasoning for HSIC versus TEVA.
HSIC leads by 12 points.

HSIC scores 67/100 (Buy) versus TEVA at 55/100 (Watch).

HSIC Committee View
75% agreement
4 analysts

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.

Bull Case
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
TEVA Committee View
50% agreement
6 analysts

The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.63 across 21 articles, 14d). Value Analyst remains cautious — p/e of 57.5 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • P/E of 57.5 is expensive by classic value standards — Value
  • Price-to-book of 4.9x prices in significant intangible value — Value
  • Debt-to-equity of 2.12 adds balance-sheet risk to the value case — Value
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
HSIC Full Analysis TEVA Full Analysis